Bayer has launched worldwide its new Rapidpoint 405 critical care blood gas analyser. The point of care system offers a fully integrated CO-oximetry module along with five new haemoglobin tests for the assessment of medical emergencies such as hypoxia, septic shock, multiple organ failure and acute respiratory distress syndrome. The system, which can be monitored remotely from a central laboratory, also offers electrolyte, pH, glucose and haematocrit testing. The company has also received US FDA approval for its Acensia Breeze blood glucose monitor for diabetics, which it plans to launch in the third quarter.
Bayer launches POC (point-of-care) CO-oximetry blood gas system:
Bayer has launched worldwide its new Rapidpoint 405 critical care blood gas analyser. The point of care system offers a fully integrated CO-oximetry module along with five new haemoglobin tests for the assessment of medical emergencies such as hypoxia, septic shock, multiple organ failure and acute respiratory distress syndrome. The system, which can be monitored remotely from a central laboratory, also offers electrolyte, pH, glucose and haematocrit testing. The company has also received US FDA approval for its Acensia Breeze blood glucose monitor for diabetics, which it plans to launch in the third quarter.